These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. A third-generation IMiD for MM. Cavo M Blood; 2011 Sep; 118(11):2931-2. PubMed ID: 21921051 [No Abstract] [Full Text] [Related]
31. [Diagnosis and management guideline for multiple myeloma]. Murakami H; Handa H; Saitoh T Nihon Rinsho; 2007 Dec; 65(12):2167-76. PubMed ID: 18069257 [TBL] [Abstract][Full Text] [Related]
32. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials. Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209 [TBL] [Abstract][Full Text] [Related]
33. Myeloma: making sense of a complex blood cancer. Kelly MB; Meenaghan T; Dowling M Br J Nurs; 2010 Dec 9-2011 Jan 13; 19(22):1415-21. PubMed ID: 21139523 [TBL] [Abstract][Full Text] [Related]
34. Initial therapy in multiple myeloma: investigating the new treatment paradigm. Kettle JK; Finkbiner KL; Klenke SE; Baker RD; Henry DW; Williams CB J Oncol Pharm Pract; 2009 Sep; 15(3):131-41. PubMed ID: 19276138 [TBL] [Abstract][Full Text] [Related]
35. Bortezomib just for induction or also for maintenance in myeloma patients with renal impairment? San Miguel JF Haematologica; 2014 Jan; 99(1):5-6. PubMed ID: 24425688 [No Abstract] [Full Text] [Related]
36. Pomalidomide therapy for multiple myeloma and myelofibrosis: an update. Lacy MQ; Tefferi A Leuk Lymphoma; 2011 Apr; 52(4):560-6. PubMed ID: 21338284 [TBL] [Abstract][Full Text] [Related]
37. Genomic stratification of multiple myeloma treated with novel agents. Jiang A; Reece D; Chang H Leuk Lymphoma; 2012 Feb; 53(2):202-7. PubMed ID: 21823830 [TBL] [Abstract][Full Text] [Related]
38. NICE guidance on pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib. Burke MJ; George E; Adler AI Lancet Oncol; 2015 May; 16(5):492-3. PubMed ID: 25818587 [No Abstract] [Full Text] [Related]
39. The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Laubach JP; Mahindra A; Mitsiades CS; Schlossman RL; Munshi NC; Ghobrial IM; Carreau N; Hideshima T; Anderson KC; Richardson PG Leukemia; 2009 Dec; 23(12):2222-32. PubMed ID: 19741729 [TBL] [Abstract][Full Text] [Related]